MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Low dose of losartan
Drug: Low dose of telmisartan
Drug: High dose of telmisartan
Drug: High dose of losartan
First Posted Date
2014-10-21
Last Posted Date
2014-10-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
330
Registration Number
NCT02269176

Tolerability of Asasantin in Healthy Female and Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Asasantin ER
Drug: Placebo
First Posted Date
2014-10-21
Last Posted Date
2014-10-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
100
Registration Number
NCT02269228

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIIL 284 BS
Drug: Placebo
Drug: Prednisone
First Posted Date
2014-10-20
Last Posted Date
2014-10-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
20
Registration Number
NCT02268149

Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Asasantin®
Drug: Acetylsalicylic acid high dose
Drug: Acetylsalicylic acid low dose
First Posted Date
2014-10-20
Last Posted Date
2014-10-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
27
Registration Number
NCT02268773

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

Phase 1
Terminated
Conditions
Healthy
Interventions
Drug: Placebo
Drug: BIIB 722 CL
First Posted Date
2014-10-20
Last Posted Date
2014-10-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
10
Registration Number
NCT02268604

Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BILN 2061 ZW single rising doses
Drug: BILN 2061 ZW fixed dose
Drug: Placebo
Other: Standardized breakfast
First Posted Date
2014-10-20
Last Posted Date
2014-10-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
103
Registration Number
NCT02268760

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

Phase 1
Terminated
Conditions
Healthy
Interventions
Drug: BIII 890 CL
Drug: Placebo
First Posted Date
2014-10-20
Last Posted Date
2014-10-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
76
Registration Number
NCT02268136

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: empagliflozin/metformin
Drug: metformin
Drug: empagliflozin
First Posted Date
2014-10-17
Last Posted Date
2017-03-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02266472
Locations
🇩🇪

Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBB 515 BS
Drug: Placebo
Drug: Pravastatin
First Posted Date
2014-10-17
Last Posted Date
2014-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
60
Registration Number
NCT02266485

Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders

First Posted Date
2014-10-17
Last Posted Date
2014-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02266524
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy